Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats.
about
Clinical pharmacology of portal hypertension.Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension.Eucapnic intermittent hypoxia augments endothelin-1 vasoconstriction in rats: role of PKCdelta.Current pharmacotherapy in the management of cirrhosis: focus on the hyperdynamic circulation.A somatostatin analog improves tilt table tolerance by decreasing splanchnic vascular conductanceTherapeutic potential of targeting the renin angiotensin system in portal hypertension.Reticulon 4B (Nogo-B) is a novel regulator of hepatic fibrosisThe effect of octreotide on urine output during orthotopic liver transplantation and early postoperative renal function; a randomized, double-blind, placebo-controlled trialAcute kidney injury in cirrhosis.Pathophysiology of portal hypertension and its clinical links.Size mismatch in liver transplantation.Prevention and treatment of variceal haemorrhage in 2017.Pathophysiology of portal hypertension and esophageal varicesRole of HSP-90 for increased nNOS-mediated vasodilation in mesenteric arteries in portal hypertension.Modulation of hepatic perfusion did not improve recovery from hepatic outflow obstruction.Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis.Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist.Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension.Effects of long-term octreotide treatment on the response of portal-systemic collaterals to vasopressin in portal hypertensive rats.A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study.Somatostatin therapy protects porcine livers in small-for-size liver transplantation.
P2860
Q34399357-75093970-7396-4508-9454-FD6F7D321A1DQ34559070-5416BEA7-1B63-4614-9A96-EFE6ABDB4135Q34666757-B6073706-D0B7-42A2-A824-D0CC7FBADDB0Q35124682-03FCEA0D-A05E-4869-BA49-60E7DBB27A2CQ35994705-E5D83E6A-5C99-42FE-8143-44E5FE0E5133Q36769062-C9743D88-AD64-4C9B-BCAF-FDE658AA61D2Q36886269-C3650E3E-BB94-40BE-A963-7DFAB3AA471AQ37315198-42B03A43-B761-493F-830F-06FF96B54284Q37323711-888F4801-B19A-4EE5-98AB-D713E70549F7Q38371453-D844481E-037C-44DF-8FC0-C258A1585386Q38913036-2130DBFF-7A84-4E93-9F45-7AC06D5547C0Q39067320-AB87767F-6482-48F7-8B61-61A42020750FQ39607845-7EC5C253-DD85-4543-85B3-B8D49C8A709CQ40094604-386F79AC-FCD6-4F7F-961D-7E8713C04BC9Q41036385-D66B7B0A-7EB2-4D84-A39D-830B99DA6713Q42468400-B92A8A85-3915-409F-97AC-975D3A65930AQ43263666-B4761ACA-B94F-415A-A2B1-6E80DA91614BQ43288624-64611FC8-1098-4028-AC53-9B018B78CB34Q44004400-B055615B-4105-4803-A672-3658FBCB0612Q44159478-57C13FF0-51A7-4D15-B46A-D288D630F0C7Q47580556-6865789A-F78D-4C3B-94F2-51C4D6F0FFD3
P2860
Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@ast
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@en
type
label
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@ast
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@en
prefLabel
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@ast
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@en
P2093
P356
P1433
P1476
Octreotide potentiates PKC-dep ...... hypertensive and control rats.
@en
P2093
P304
P356
10.1053/GAST.2001.22529
P407
P577
2001-03-01T00:00:00Z